It’s taking too long for people with Crohn’s and colitis to be diagnosed, but the sooner you start that process and ask for ...

Tremfya is the first and only fully-human, dual-acting IL-23p19 subunit inhibitor approved in both ulcerative colitis and ...

New guidelines, developed and led by experts at the University of Nottingham, will help clinicians to better treat the ...

In a human-mouse xenogeneic GvHD (xGvHD) model, ALTB-268 significantly improved survival, reduced disease severity score and body weight loss, and decreased human CD4+ and CD8+ T cells, while ...

Cristcot, a clinical-stage pharmaceutical company advancing innovative therapies for gastrointestinal diseases, participated in the 5th annual GI ReConnect meeting in Aurora, Colorado, as a Gold ...

Two biomarker tests -- one for blood and the other for stool -- are mainstays in the treatment of inflammatory bowel disease ...

Phase 1 data for Spyre Therapeutics, Inc.'s SPY002 & SPY072 show promise in autoimmune treatments. Advancing to Phase 2 ...

Patients with ulcerative colitis have a higher risk for cancer than the general population, with variations in cancer incidence more pronounced with age than with treatment status.